You, Sir, Are No Apple (but We Still Want to Buy You)

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The proxy fight surrounding Roche's (OTC: RHHBY) hostile bid for Illumina (Nasdaq: ILMN  ) has reached the ruckus level of the 1988 vice presidential debates.

Like Dan Quayle, Illumina set itself up by citing Xconomy reporter Luke Timmerman's comment that "Illumina is like the Apple of the genomics business."

To which Roche responded, "There is one glaring difference between Illumina and Apple -- Illumina's MiSeq and HiSeq ARE NOT the iPhone and the iPad," before adding, "unlike at Apple stores, crowd control of eager buyers has not been a problem for Illumina."

A retort in its best Lloyd Bentsen voice, "I've used Apple products, I've been to the Genius Bar, I've spent money on overpriced Apple products. Illumina, you're no Apple," would have been funnier and probably more effective.

Either way, I think it's safe to assume Roche won't propose to change the name of the company to iLlumina at the shareholder meeting next week.

What Roche does want is for shareholders to support its slate of nominees so it can facilitate the hostile takeover internally. Big hint, Roche: Insulting the company the shareholders own probably isn't the best way to get shareholders on your side.

Roche is in a desperate situation. Those inclined to think the $51 per share offer is reasonable might as well just sell their share on the open market where they can currently get a higher offer. Assuming it stays that way going into next week's shareholder meeting, I see very few shareholders voting for Roche's nominees.

Roche tries to skirt the point by characterizing its offer as a "more than reasonable starting point for negotiations." But investors should see through the contention. Unless Roche's nominees go rogue, Illumina will get sold for pretty close to the current offer.

At this point, it looks like Illumina is content to just sit back and wait for Roche to continue to bid against itself. Of course the worry for shareholders is that Roche gets fed up and walks away. Illumina is clearly the best fit, but there are other fish in the genetic-analysis sea. Life Technologies (Nasdaq: LIFE  ) , Pacific Biosciences of California (Nasdaq: PACB  ) , Complete Genomics (Nasdaq: GNOM  ) , and a few smaller private companies are all potential options.

Like debates where candidates insult each other, proxy fights are fun to watch. Unfortunately there are no exit polls -- or iPhone apps -- to get a read on which way this one will go. Investors would be better off with other high-tech stocks.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Apple. Motley Fool newsletter services have recommended buying shares of Apple, Pacific Biosciences of California, and Illumina. Motley Fool newsletter services have recommended creating a bull call spread position in Apple. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 14, 2012, at 11:01 PM, BradGessner wrote:

    Illumina machines actually do have an iPhone app so you can moniter your sequencing when you're home in bed with your spouse (if that's what makes you happy).

    Roche should just get real and bring a proper offer so we don't have to play this cute little "hardball" dance.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1860880, ~/Articles/ArticleHandler.aspx, 10/26/2016 5:15:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
ILMN $139.95 Up +1.77 +1.28%
Illumina CAPS Rating: *****
GNOM.DL $0.00 Down +0.00 +0.00%
Complete Genomics CAPS Rating: **
LIFE.DL $0.00 Down +0.00 +0.00%
Life Technologies… CAPS Rating: ***
PACB $8.60 Down -0.15 -1.71%
Pacific Bioscience… CAPS Rating: ***